|
|
Serum COMP in Juvenile Idiopathic Arthritis |
Focus letter 4, 2010 |
Reduced serum COMP level may be a useful marker of active disease and growth retardation in juvenile idiopathic arthritis. |
| In 2006 Urikami et al published a study[4] where they showed that children with systemic juvenile idiopathic arthritis had decreased serum COMP levels compared to healthy controls. They suggest that serum COMP could be used in children as a biomarker indicating growth impairment based on the fact that serum COMP reflects cartilage turnover. During the last two years these results have been verified in publications from three[1-3] non-related research groups. In these studies it was furthermore shown that the serum COMP levels were positively correlated to growth velocity[1], increased in the remission phase after treatment[2], and finally were lower in patients with joint space narrowing and joint erosions[3]. |
Serum COMP might be a useful prognostic risk marker for severe growth impairment in recent-onset juvenile idiopathic arthritis. |
The aim of this study was to evaluate the association between the serum COMP levels in recent-onset juvenile idiopathic arthritis (JIA)(n=87, mean age = 6.9 years) and growth velocity. Six patients had systemic-onset disease and 29 patients had polyarticular-onset disease. Serum COMP was measured at inclusion and growth velocity after a mean period of 196 days. The serum COMP levels of the patients showed a significant (p=0.0003) correlation (r=0.38) to growth velocity and were significantly (p<0.0001) lower than in healthy children. The authors conclude that the serum COMP level might be a useful prognostic risk marker in JIA for severe growth impairment. |
| Bjørnhart, B; Juul, A; Nielsen, S; Zak, M; Svenningsen, P; Müller K: Cartilage oligomeric matrix protein in patients with juvenile idiopathic arthritis: relation to growth and disease activity.
J Rheumatol 2009 Aug, 36(8): 1749-54. PubMed Abstract |
An increase in serum COMP might be a reliable biomarker to show that retarded growth is improved by treatments in systemic juvenile idiopathic arthritis. |
| The main objective of this publication was to evaluate if serum COMP could be used as a biomarker to monitor the treatment effect of tocilizumab (anti-interleukin-6 receptor) in systemic juvenile idiopathic arthritis (sJIA). Sera from 11 sJIA patients treated with tocilizumab were obtained in both the active and the remission phase of the treatment. The period between the two serum samples varied between 2 to 55 months with an average time of 23 months. The serum COMP levels were significantly (p<0.05) higher in the remission phase after treatment. The authors conclude that an increase in serum COMP might be a reliable biomarker to show that retarded growth is improved by treatments such as tocilizumab. |
Nakajima, S.; Naruto, T.; Miyamae, T.; Imagawa, T.; Mori, M.; Nishimaki, S.; Yokota, S.:
Improvement of reduced serum cartilage oligomeric matrix protein levels insystemic juvenile idiopathic arthritis patients treated with theanti-interleukin-6 receptor monoclonal antibody tocilizumab.
Mod Rheumatol. 2009, 19(1): 42-6. Epub 2008 Aug 23. PubMed Abstract |
Serum COMP together with RFs and anti-CCP antibodies are important in the assessment of JIA patients to determine severity of the disease. |
| The aim of this study was to evaluate a panel of biomarkers (CRP, ERS, RFs, anti-CCP and COMP) as markers of joint damage in a cross-sectional study of children (n=68) with juvenile idiopathic arthritis (JIA). Nine patients had a systemic-onset disease and 42 had polyarthritis. JIA patients with joint erosion (p<0.05) or joint space narrowing (p<0.01) had significantly lower serum COMP levels compared with patients without these lesions. Serum COMP also showed a low but significant (p<0.05) negative correlation (r=-0.308) to IgM RF. In multiple logistic regression serum COMP was shown to be an independent factor correlating to joint space narrowing (OR 0.212, p=0.015) but not to joint erosions. The authors conclude that serum COMP together with RFs and anti-CCP antibodies are important in the assessment of JIA patients to determine severity of the disease. |
| Gilliam, BE.; Chauhan, AK.; Low, JM.; Moore, TL.: Measurement of biomarkers injuvenile idiopathic arthritis patients and their significant association withdisease severity: a comparative study.
Clin Exp Rheumatol. 2008 May-Jun, 26(3): 492-7. PubMed Abstract |
References |
- Bjørnhart B, Juul A, Nielsen S, Zak M, Svenningsen P, Müller K.: Cartilageoligomeric matrix protein in patients with juvenile idiopathic arthritis:relation to growth and disease activity.
J Rheumatol. 2009 Aug, 36(8): 1749-54. Epub 2009 Jul 15. PubMed Abstract
- Nakajima, S.; Naruto, T.; Miyamae, T.; Imagawa, T.; Mori, M.; Nishimaki, S.; Yokota, S..: Improvement of reduced serum cartilage oligomeric matrix protein levels insystemic juvenile idiopathic arthritis patients treated with theanti-interleukin-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 2009, 19(1): 42-6. Epub 2008 Aug 23. PubMed Abstract
- Gilliam, BE.; Chauhan, AK.; Low, JM.; Moore, T.: Measurement of biomarkers injuvenile idiopathic arthritis patients and their significant association withdisease severity: a comparative study.
Clin Exp Rheumatol. 2008 May-Jun, 26(3): 492-7. PubMed Abstract
- Urakami, T.; Manki, A.; Inoue, T.; Oda, M.; Tanaka, H.; Morishima, T.: Clinicalsignificance of decreased serum concentration of cartilage oligomeric matrixprotein in systemic juvenile idiopathic arthritis.
J Rheumatol. 2006 May, 33(5): 996-1000. PubMed Abstract
|
|
|
FOCUS ON
|
|
|
